AstraZeneca Results Presentation Deck

Double-digit growth across US, EM and EU 9M Total Revenue ex-COVID-19 (USD millions) and Growth vs PY +14% 13,940 Strong growth across regions, therapy areas US +20% Ex-China: +37% China: +6% Emerging Markets +14% CEO Opening Remarks 6,748 Europe +8% 3,726 Financial Results Established Rest of World Oncology +20% 13,458 Strong growth across Oncology, CVRM, R&I and Rare Disease underpinning FY outlook 9M Total Revenue (USD millions) and Growth vs PY ■Oncology +19% BioPharmaceuticals 7,926 CVRM +9% 4,729 Rare Disease R&I +12% 5,793 Rare Disease CEO Closing Remarks 6 All growth rates at CER. Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. Total Revenue and growth rates by region reflect figures ex-COVID-19 medicines. EM = Emerging Markets; EU = Europe; CER = constant exchange rates; CVRM = Cardiovascular, Renal & Metabolism; R&I = Respiratory & Immunology; V&I = Vaccines & Immune Therapies. (73%) 944 V&I

View entire presentation